65,437 trials
Fibromyalgia
Primary: Patient Global Impression of Change (PGIC) Responder Rate at End of Study — 36; 83; 137; 96 participants — p=<0.001
Joint Diseases
Primary: Harris Hip Total Score — 50.5; 50.8; 75.7; 73.6 Units on a scale — p=0.001
Arrhythmia · Tachycardia · Atrial Fibrillation
Primary: Time Per Patient From a Clinical Event to a Clinical Decision in Response to Arrhythmias, Cardiovascular (CV) Disease Progression, and Device Issues — 4.6; 22.0 days…
Rheumatoid Arthritis
Primary: DAS-28 (Disease Activity Score in 28 Joints) — 2.87; 2.66 Units on a Scale
Dental Plaque
Primary: ph of Dental Plaque After Sucrose Challenge — 4.88; 5.04; 4.98 ph of dental plaque — p=0.05
Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR). — 90…
Adverse Effect of Contact Lens Solution
Primary: Subjective Assessment of Comfort and Cleanliness — 89.71; 89.26; 87.45; 86.63 Scores on a scale
Diabetes Mellitus, Type 1
Primary: Usability of the X54 Insulin Pump Meets Expectations — 5.9 Scores on a scale
Psoriasis
Primary: Proportion of Patients Who Achieved a ≥ 75% Decrease in Psoriasis Scalp Severity Index (PSSI) Score at 12 Weeks — 0.111; 0.274 Proportion of patients — p=0.1054
Healthy · Asthma
Primary: Number of Participants by of Adverse Events Following a Skin Test Procedure — 1; 3; 0; 0 participants
Excessive Sleepiness
Primary: Change From Baseline to Endpoint in Number of Contiguous Activated Voxels Meeting Predefined Threshold in Dorsolateral Prefrontal Cortex (DLPFC) on Functional Magnetic…
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Number of Participants With Complete Remission — 0; 0; 0; 2 participants
Breast Cancer
Primary: Number of Participants With Disease-Free Survival Events — 287; 333 Participants — p=0.0043
Essential Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8 — -8.01; -6.30 mmHg
West Nile Fever
Primary: Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion). — 0; 21; 36; 27 Participants